We've talked before about how government policy has prevented the egg industry from using vaccines to fight Highly Pathogenic Avian Influenza. But if there was a policy shift tomorrow, and producers were given the green light to immunize their birds, what would that effort even look like? Where would the vaccines comes from? How would we know they're safe and effective? How much would they cost? And who would be expected to foot that bill?

Joel Harris is the co-founder of Genvax. An economist by trade, he has nearly 20 years of experience working in the field of animal vaccine development. His company, Genvax, uses an RNA platform that allows them to quickly develop vaccines, and respond rapidly to emerging diseases. Today, Joel walks us through the complex logistics and economics of vaccine development, as well as his own companies efforts to develop a tool to fight HPAI.

This is a fascinating issue that sits at the intersection of business, politics and science. Joel does a great job of breaking it all down for us, and shedding light on the inner workings of a niche but vital industry.

Are you an egg industry pro? Reach out to be a guest on the show! Connect with us on LinkedIn and Instagram. And please rate Eggheads on Spotify and Apple Podcasts.

If you're interested in sponsoring a future episode of Eggheads, you can contact us by filling out this form.